Literature DB >> 1862205

Treatment of age-associated memory impairment with guanfacine.

W J McEntee1, T H Crook, L R Jenkyn, W Petrie, G J Larrabee, D J Coffey.   

Abstract

Alpha2 adrenergic agonists have been shown to improve memory test performance in amnesic humans and aged nonhuman primates. In a group of drugs in this class that were tested for their effects on age-related memory impairments in aged monkeys, guanfacine was the most effective for improving mnemonic function at doses that were without significant side effects. These data prompted studies of guanfacine for its effect on learning and memory in persons with age-associated memory impairment (AAMI), the results of which are now reported. The data suggest that guanfacine may have modest mood-improving effects but had no significant effects on learning and memory in the subjects tested.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1862205

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  5 in total

1.  Age-Associated Memory Impairment.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

Review 2.  Cognition enhancers in age-related cognitive decline.

Authors:  W J Riedel; J Jolles
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

3.  Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial.

Authors:  Nicole M Barcelos; Peter H Van Ness; Allison F Wagner; Martha G MacAvoy; Adam P Mecca; George M Anderson; Mark Trentalange; Keith A Hawkins; Mary Sano; Amy F T Arnsten; Christopher H van Dyck
Journal:  Neurobiol Aging       Date:  2018-05-31       Impact factor: 4.673

Review 4.  New approaches for the quantification and targeting of noradrenergic dysfunction in Alzheimer's disease.

Authors:  Michael David; Paresh A Malhotra
Journal:  Ann Clin Transl Neurol       Date:  2022-03-15       Impact factor: 4.511

5.  Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments.

Authors:  Karen Hoang; Hilary Watt; Mara Golemme; Richard J Perry; Craig Ritchie; Danielle Wilson; James Pickett; Chris Fox; Robert Howard; Paresh A Malhotra
Journal:  Trials       Date:  2022-08-01       Impact factor: 2.728

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.